Baidu
map

Nature Medicine:全球万人晚期癌症测序成果发布,或开启癌症诊疗新模式

2017-05-15 佚名 奇点网

今天,《自然 医学》杂志上刊登了一个有关癌症的里程碑式临床研究[1]!美国最好的癌症中心之一,纪念斯隆凯特琳癌症研究中心(Memorial Sloan Kettering Cancer Center,简称MSK)的研究人员利用他们独有的肿瘤检测技术MSK-IMPACT对超过10000名晚期癌症患者进行了基因测序,这是目前转移性癌症患者中最大规模的肿瘤测序研究。

今天,《自然 医学》杂志上刊登了一个有关癌症的里程碑式临床研究[1]!美国最好的癌症中心之一,纪念斯隆凯特琳癌症研究中心(Memorial Sloan Kettering Cancer Center,简称MSK)的研究人员利用他们独有的肿瘤检测技术MSK-IMPACT对超过10000名晚期癌症患者进行了基因测序,这是目前转移性癌症患者中最大规模的肿瘤测序研究。


研究中患者的癌症类型分布研究中患者的癌症类型分布

基于测序结果,有1000多名患者参与了个性化的临床治疗实验。现在,研究人员不但可以确定癌症的类型和扩散程度,还能知道是哪些突变驱动着癌细胞,然后帮助患者选择最可能起效的疗法。

这项研究共包括10945例肿瘤样本,来自10336名患者。研究的通讯作者,遗传学家Michael Berger博士说:“这项研究代表了MSK在临床测序领域的一个‘高潮’,对我们来说,这前10000多名患者是一项大投资,我们通过他们建立了‘数据库’,其中有巨大的可挖掘潜力,这前10000名患者是我们的一个里程碑。”


Michael Berger博士

MSK-IMPACT(Integrated Mutation Profiling of Actionable Cancer Targets)是一个更加全面的癌症测序技术。目前,常规针对癌症的测序只在少数几种癌症中进行。相比之下,MSK-IMPACT适用于任何肿瘤类型,而且还能够检测到罕见的突变以及其他关键的遗传变异[4]。这种检测是肿瘤精准治疗的一个重要组成部分,灵活、全面的鉴定治疗中可靶向的基因。

MSK-IMPACT基于二代测序技术,它并不是对肿瘤的全基因组或蛋白编码基因进行测序,而是以过去的癌症研究为基础,确定了341个重要的“癌基因”。研究人员对患者这些基因上所有的重要区域都进行了测序,可以检测到基因上所有蛋白编码区突变、拷贝数变化(CNAs)、启动子突变和基因组重排。MSK的病理学系主任David S. Klimstra博士认为,这使得研究人员能够更全面的了解患者的“遗传变异”情况。


从检测到出具报告的流程示意图从检测到出具报告的流程示意图

首先,研究人员比较了MSK-IMPACT与全外显子组测序(WES)的差别,通过对样本的检测,他们发现至少有9%的癌症相关突变是WES没有检测到的。而且,MSK-IMPACT能够检测到的一些很重要的,基因组重排导致的“融合基因”,WES也是检测不到的。研究人员在1597名患者(15%)中都检测到了融合基因,其中最常见的分别是TMPRSS2-ERG、EGFRvIII、EML4-ALK和EWSR1-FLI1。

而后,研究人员将MSK-IMPACT的测序结果与癌症体细胞突变目录(Catalog of Somatic Mutations in Cancer,COSMIC)数据库做了对比,发现有69%的体细胞突变数据库中都没有收录!没有与之相匹配的正常样本测序结果的对比,这些突变是很难和一些罕见的遗传变异区分开的。

根据研究人员的介绍,传统的临床试验招募患者通常是以癌症类型为标准,但基于MSK-IMPACT检测,他们可以进行新型临床研究,以基因的突变为标准,具有相同突变的患者,尽管可能癌症类型不同,但是可以使用同一种靶向药物。比如前列腺癌、肾嫌色细胞癌、胶质母细胞瘤和胃癌中都有编码区基因TP53的突变。


主要癌种和主要基因突变的对应以及突变类型的比例

TP53基因是这次研究中发现的最常见的一个突变基因,41%的患者都有携带,尤其是高级别浆液性卵巢癌(98%),食管腺癌(89%)和小细胞肺癌(85%)患者。其次是KRAS基因,携带者占所有患者的15%,有90%的胰腺癌患者和44%的结肠癌患者都携带它的突变。

研究人员选取了常见的16种肿瘤,将MSK-IMPACT的检测结果与TCGA(The Cancer Genome Atlas)数据库做对比,发现在突变位点的鉴定上是高度一致的。但是有一些TCGA中被发现突变频率很高的基因在MSK-IMPACT的检测下显示的突变频率更高,其中最具代表性的仍然是TP53,在前列腺癌中,MSK-IMPACT检测的突变频率是TCGA的4倍之多(29%和7%)。

还有一些在TCGA中突变频率不高的基因在MSK-IMPACT中却很高,例如前列腺癌中的AR基因(18%和1%)和乳腺癌中的ESR1基因(11%和4%)。这说明MSK-IMPACT检测所构建的数据库与现有的常用数据库的差异还是不小的。


TERT启动子突变(绿)和未突变(红)患者的存活率对比,从左至右依次为黑色素瘤、尿路上皮癌和甲状腺乳头状癌

除了蛋白编码基因,MSK-IMPACT也能够检测到一些重要的非编码基因,例如TERT(端粒酶逆转录酶)基因。它的启动子发生突变在膀胱癌(70%)、胶质瘤(67%)、甲状腺癌(60%)和黑色素瘤(49%)中都属常见,而这也是WES做不到的。通过MSK-IMPACT,研究人员还进一步发现,在同样类型的癌症中,有这种突变的患者的生存率明显低于没有突变的患者。

除了体细胞突变和非编码基因的检测外,MSK-IMPACT在突变标记(mutation siganures)方面的检测也不在话下,突变标记可能能够揭示患者所患癌症的原因和预测癌症疗法响应的可能性。再举个例子,DNA修复中的错配修复(MMR)缺陷就是一种突变标记,在2015年的美国临床肿瘤学会(ASCO)年会上,Johns Hopkins Kimmel癌症中心的研究人员指出,MMR缺陷的检测可以用来预测抗PD-1/PD-L1药物的响应情况,对于实现患者的“个性化治疗”来说有很大益处。


前列腺癌患者肿瘤的变化情况(红色箭头所指)


在MSK,就有一位55岁的前列腺癌患者因此而受益。这名患者没有检查出相关的常见体细胞突变,但是MSK-IMPACT的检测结果显示他的MUTYH基因上存在MMR缺陷,于是他加入了一项抗PD-L1免疫治疗药物的临床试验中,患者对药物响应良好,MRI检查显示他的肿瘤在治疗两个多月后迅速缩小!

研究人员发现,这10000多名患者中,36.7%都有至少一种可用MSK-IMPACT检测到的突变,这意味着他们可以参与一些靶向药物的临床试验。在研究中,去掉身体状况不允许的和没有治疗意愿的患者,最后有11%的患者都参与了MSK不同靶向药物的临床试验。


a:基因突变对应的FDA批准的生物标志物和药物;b:患者携带情况的分布;c:患者参与针对不同基因突变的靶向药物的临床实验数量


Berger博士指出,实际上受益于MSK-IMPACT的患者的比例还要更高一些,因为10336名患者的数量是在2016年夏天达到的,到目前为止,患者已经超过16000名,而且这一数字还在以每月600-800的增量增长着!另外,随着患者的增加,MSK-IMPACT“数据库”(数据库地址http://cbioportal.org/msk-impact)中的癌基因也从341个增加到了468个,这些增长意味着未来会有更多的患者从MSK-IMPACT受益,同时也为MSK-IMPACT数据库做出贡献。

参与了研究的Marc Ladanyi博士表示:“当我们发布了这个里程碑研究时,我想我们是正在建立一个新的癌症检测治疗模式。”

原始出处:
Ahmet Zehir, Ryma Benayed, Ronak H Shah, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine (2017) doi:10.1038/nm.4333.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1858745, encodeId=8d1b1858e4562, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jun 24 07:31:00 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882033, encodeId=b873188203359, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 18 22:31:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773619, encodeId=1ce81e7361901, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 21 14:31:00 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201699, encodeId=0bf020169900, content=可以拿来直接临床使用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6lQViaiaazgKwu3ASkx2y57ib6ISo2VFcU2BYlssBOpcOQcjB5rSVpl36mTeQD5lzAvY9wwxyOuebVA/0, createdBy=57c11919303, createdName=wl1122050, createdTime=Tue May 23 15:58:14 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577528, encodeId=92c815e7528c1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed May 17 05:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607515, encodeId=334b160e515dd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 17 05:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198468, encodeId=969e198468c5, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon May 15 20:26:50 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198454, encodeId=255c1984545d, content=真是一个里程碑式的研究,有钱就是牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aadd1680584, createdName=蔬菜, createdTime=Mon May 15 19:31:19 CST 2017, time=2017-05-15, status=1, ipAttribution=)]
    2017-06-24 jeanqiuqiu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1858745, encodeId=8d1b1858e4562, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jun 24 07:31:00 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882033, encodeId=b873188203359, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 18 22:31:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773619, encodeId=1ce81e7361901, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 21 14:31:00 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201699, encodeId=0bf020169900, content=可以拿来直接临床使用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6lQViaiaazgKwu3ASkx2y57ib6ISo2VFcU2BYlssBOpcOQcjB5rSVpl36mTeQD5lzAvY9wwxyOuebVA/0, createdBy=57c11919303, createdName=wl1122050, createdTime=Tue May 23 15:58:14 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577528, encodeId=92c815e7528c1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed May 17 05:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607515, encodeId=334b160e515dd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 17 05:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198468, encodeId=969e198468c5, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon May 15 20:26:50 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198454, encodeId=255c1984545d, content=真是一个里程碑式的研究,有钱就是牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aadd1680584, createdName=蔬菜, createdTime=Mon May 15 19:31:19 CST 2017, time=2017-05-15, status=1, ipAttribution=)]
    2017-05-18 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1858745, encodeId=8d1b1858e4562, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jun 24 07:31:00 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882033, encodeId=b873188203359, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 18 22:31:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773619, encodeId=1ce81e7361901, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 21 14:31:00 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201699, encodeId=0bf020169900, content=可以拿来直接临床使用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6lQViaiaazgKwu3ASkx2y57ib6ISo2VFcU2BYlssBOpcOQcjB5rSVpl36mTeQD5lzAvY9wwxyOuebVA/0, createdBy=57c11919303, createdName=wl1122050, createdTime=Tue May 23 15:58:14 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577528, encodeId=92c815e7528c1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed May 17 05:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607515, encodeId=334b160e515dd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 17 05:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198468, encodeId=969e198468c5, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon May 15 20:26:50 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198454, encodeId=255c1984545d, content=真是一个里程碑式的研究,有钱就是牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aadd1680584, createdName=蔬菜, createdTime=Mon May 15 19:31:19 CST 2017, time=2017-05-15, status=1, ipAttribution=)]
    2017-09-21 docwu2019
  4. [GetPortalCommentsPageByObjectIdResponse(id=1858745, encodeId=8d1b1858e4562, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jun 24 07:31:00 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882033, encodeId=b873188203359, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 18 22:31:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773619, encodeId=1ce81e7361901, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 21 14:31:00 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201699, encodeId=0bf020169900, content=可以拿来直接临床使用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6lQViaiaazgKwu3ASkx2y57ib6ISo2VFcU2BYlssBOpcOQcjB5rSVpl36mTeQD5lzAvY9wwxyOuebVA/0, createdBy=57c11919303, createdName=wl1122050, createdTime=Tue May 23 15:58:14 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577528, encodeId=92c815e7528c1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed May 17 05:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607515, encodeId=334b160e515dd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 17 05:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198468, encodeId=969e198468c5, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon May 15 20:26:50 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198454, encodeId=255c1984545d, content=真是一个里程碑式的研究,有钱就是牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aadd1680584, createdName=蔬菜, createdTime=Mon May 15 19:31:19 CST 2017, time=2017-05-15, status=1, ipAttribution=)]
    2017-05-23 wl1122050

    可以拿来直接临床使用?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1858745, encodeId=8d1b1858e4562, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jun 24 07:31:00 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882033, encodeId=b873188203359, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 18 22:31:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773619, encodeId=1ce81e7361901, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 21 14:31:00 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201699, encodeId=0bf020169900, content=可以拿来直接临床使用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6lQViaiaazgKwu3ASkx2y57ib6ISo2VFcU2BYlssBOpcOQcjB5rSVpl36mTeQD5lzAvY9wwxyOuebVA/0, createdBy=57c11919303, createdName=wl1122050, createdTime=Tue May 23 15:58:14 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577528, encodeId=92c815e7528c1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed May 17 05:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607515, encodeId=334b160e515dd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 17 05:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198468, encodeId=969e198468c5, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon May 15 20:26:50 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198454, encodeId=255c1984545d, content=真是一个里程碑式的研究,有钱就是牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aadd1680584, createdName=蔬菜, createdTime=Mon May 15 19:31:19 CST 2017, time=2017-05-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1858745, encodeId=8d1b1858e4562, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jun 24 07:31:00 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882033, encodeId=b873188203359, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 18 22:31:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773619, encodeId=1ce81e7361901, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 21 14:31:00 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201699, encodeId=0bf020169900, content=可以拿来直接临床使用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6lQViaiaazgKwu3ASkx2y57ib6ISo2VFcU2BYlssBOpcOQcjB5rSVpl36mTeQD5lzAvY9wwxyOuebVA/0, createdBy=57c11919303, createdName=wl1122050, createdTime=Tue May 23 15:58:14 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577528, encodeId=92c815e7528c1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed May 17 05:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607515, encodeId=334b160e515dd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 17 05:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198468, encodeId=969e198468c5, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon May 15 20:26:50 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198454, encodeId=255c1984545d, content=真是一个里程碑式的研究,有钱就是牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aadd1680584, createdName=蔬菜, createdTime=Mon May 15 19:31:19 CST 2017, time=2017-05-15, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1858745, encodeId=8d1b1858e4562, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jun 24 07:31:00 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882033, encodeId=b873188203359, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 18 22:31:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773619, encodeId=1ce81e7361901, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 21 14:31:00 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201699, encodeId=0bf020169900, content=可以拿来直接临床使用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6lQViaiaazgKwu3ASkx2y57ib6ISo2VFcU2BYlssBOpcOQcjB5rSVpl36mTeQD5lzAvY9wwxyOuebVA/0, createdBy=57c11919303, createdName=wl1122050, createdTime=Tue May 23 15:58:14 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577528, encodeId=92c815e7528c1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed May 17 05:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607515, encodeId=334b160e515dd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 17 05:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198468, encodeId=969e198468c5, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon May 15 20:26:50 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198454, encodeId=255c1984545d, content=真是一个里程碑式的研究,有钱就是牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aadd1680584, createdName=蔬菜, createdTime=Mon May 15 19:31:19 CST 2017, time=2017-05-15, status=1, ipAttribution=)]
    2017-05-15 dhzzm

    学习了分享了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1858745, encodeId=8d1b1858e4562, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jun 24 07:31:00 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882033, encodeId=b873188203359, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 18 22:31:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773619, encodeId=1ce81e7361901, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 21 14:31:00 CST 2017, time=2017-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201699, encodeId=0bf020169900, content=可以拿来直接临床使用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6lQViaiaazgKwu3ASkx2y57ib6ISo2VFcU2BYlssBOpcOQcjB5rSVpl36mTeQD5lzAvY9wwxyOuebVA/0, createdBy=57c11919303, createdName=wl1122050, createdTime=Tue May 23 15:58:14 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577528, encodeId=92c815e7528c1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed May 17 05:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607515, encodeId=334b160e515dd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 17 05:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198468, encodeId=969e198468c5, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon May 15 20:26:50 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198454, encodeId=255c1984545d, content=真是一个里程碑式的研究,有钱就是牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aadd1680584, createdName=蔬菜, createdTime=Mon May 15 19:31:19 CST 2017, time=2017-05-15, status=1, ipAttribution=)]
    2017-05-15 蔬菜

    真是一个里程碑式的研究,有钱就是牛

    0

相关资讯

13万人大数据:长期服用阿司匹林减少癌症死亡

长期服用阿司匹林能降低几种主要癌症死亡率(图片来源:《Time》)我们都听过规律服用阿司匹林可以降低心脏病和中风的风险,现在这一益处又扩展到了降低某些癌症的死亡率。在近期举行的美国癌症研究协会(AACR)年会上,来自著名医院麻省总医院(Massachusetts General Hospital)和哈佛医学院(Harvard Medical School)的一项研究发现,规律服用阿司匹林可

Ann Oncol:肌酸能否缓解癌症厌食/减重综合征

本项研究为多项试点研究,包括一项在结肠直肠癌患者中的研究,表明肌酸,一种氨基酸衍生物,可以增强肌肉,提高强度,从而缓解癌症厌食症/体重减轻综合征。

Gastroenterology:切断癌症转移途径,关键在哪里?

【癌症转移:缺氧意想不到的危险】在许多肿瘤中占优势的低氧浓度增加了其转移到其他组织的倾向。 Heiko Hermeking教授领导的慕尼黑路德维希 - 马克西米利安大学(LMU)的研究人员已经发现了将这两种现象联系起来的分子机制。许多积极生长的肿瘤血液供应不足,这限制了肿瘤内可用的氧气浓度,这种状况称为缺氧。肿瘤缺氧具有几个显著的后果:相对缺氧部分是由于这种实体肿瘤对辐射和化疗具有相对的抵抗力,同

Sci Transl Med:惊人发现!揭秘免疫疗法为何“无效”?

5月10日,免疫疗法再次登上了Science Translational Medicine杂志的封面(论文标题:In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy)。来自麻省总医院(Massachusetts General Hospital ,

JAMA:维生素D预防癌症的真相

我们都知道维生素D可以帮助钙的吸收、促进骨骼健康,也能增强免疫力。最近的一些研究发现维生素D还可以预防结肠癌和乳腺癌。但这种关联到底有多强呢?最近发表在著名医学期刊《Journal of the American Medical Association》(简称JAMA)上的一篇文章也许可以回答这个问题。这项历时4年的研究将2300名绝经后女性随机分成两组,一组每天口服2000个国际单位(IU)的维

Nat Genet:启动子突变也会影响胰腺癌发生

在过去的十年时间里,科学家们通过对外显子进行测序在发现癌症驱动基因方面取得了显著进展。如果癌症是因基因突变累积而导致的疾病,我们就需要知道不同癌症类型中究竟存在哪些基因改变。在一项发表在国际学术期刊Nature Genetics上的研究中,来自冷泉港实验室的一支研究团队对癌细胞中除外显子之外其余98%的DNA进行了研究。他们收集了308名胰腺

Baidu
map
Baidu
map
Baidu
map